title: Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.
abstract: BACKGROUND
  Pharmacotherapies improve sexual function following treatments for localized prostate cancer; however, patterns of care remain unknown. Aim. To ascertain post-treatment utilization of pharmacotherapies for erectile dysfunction (ED) using a population-based approach.
  
  
  METHODS
  We identified 38,958 men who underwent definitive treatment for localized prostate cancer during 2003-2006 from the MarketScan Medstat data.
  
  
  METHODS
  We compared the use of ED pharmacotherapy at baseline (up to 3 months prior) and up to 30 months following radical prostatectomy (RP) or radiotherapy (RT) for localized prostate cancer by utilizing National Drug Classification codes for phosphodiesterase-5 inhibitors (PDE5I), intracavernosal injectable therapies (IT), urethral suppositories and vacuum erection devices (VED). In adjusted analyses, we controlled for the effect of age, comorbidity, type of treatment, health plan and use of adjuvant hormone therapy on the use of pharmacotherapies. Results. Men undergoing RP vs. RT were younger with less co-morbid conditions. Utilization of PDE5I was up to three times greater for men undergoing RP vs. RT, 25.6% vs. 8.8%, (P < 0.0001) in the first post-treatment year, and usage of these agents was greatest for men undergoing minimally-invasive RP procedures. A higher percentage of men also used IT, suppositories and VED after RP vs. RT (P < 0.001). However, more men in the RT group received adjuvant hormonal therapy (39.53% vs. 5.25% for RP, P < 0.01). In adjusted analyses, men undergoing RP vs. RT were more than two times likely (OR 2.1, 95% CI 1.98, 2.26) to use PDE5I post-treatment while men on adjuvant hormonal therapy were less likely to use PDE5I (OR 0.74, 95% CI 0.70-0.79, P < 0.0001).
  
  
  CONCLUSIONS
  Men undergoing RP vs. RT, particularly minimally-invasive RP, are more likely to employ IT, suppositories, VED, and PDE5I pharmacotherapy post-treatment.
authors.affiliation: Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Michaella M
authors.initials: MM
authors.lastname: Prasad
authors.forename: Sandip M
authors.initials: SM
authors.lastname: Prasad
authors.forename: Nathanael D
authors.initials: ND
authors.lastname: Hevelone
authors.forename: Xiangmei
authors.initials: X
authors.lastname: Gu
authors.forename: Aaron C
authors.initials: AC
authors.lastname: Weinberg
authors.forename: Stuart R
authors.initials: SR
authors.lastname: Lipsitz
authors.forename: Ganesh S
authors.initials: GS
authors.lastname: Palapattu
authors.forename: Jim C
authors.initials: JC
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications; D011467:Prostate / Q000528:radiation effects / Q000601:surgery; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors